FLIPI24 Model

FLIPI24 is a prognostic model and clinical trial enrichment tool for patients with newly diagnosed follicular lymphoma. The model was developed and externally validated on more than 10,000 patients with follicular lymphoma from 10 international cohorts and clinical trials.

The model provides the probability of an event in the first 24 months of treatment; and identifies three risk groups for risk stratification and clinical trial design. Patients with low-risk FLIPI24 results have excellent outcomes with current standard of care therapy and a less than 5% risk of dying of lymphoma in the first 10 years after diagnosis. Patients with high-risk FLIPI24 should be considered a priority for enrollment in clinical trials.

Prediction of event-free survival at 24 months assumes CD20 antibody plus CHOP or bendamustine-based chemotherapy with a 50% likelihood of CD20 antibody maintenance.

The information is provided for educational purposes only. Please read the product’s disclaimer prior to using it.

Access the risk calculator